5 research outputs found
Comparison of central corneal thickness measurements in healthy eyes using three popular diagnostic devices
Kornea Neovaskülarizasyonunda Subkonjonktival ve İntrakorneal Bevasizumab Enjeksiyonu Sonuçlarımız
Autologous serum eye-drops and enhanced epithelial healing time after photorefractive keratectomy.
The aim of the study is to test whether use of autologous serum eye-drops can provide earlier epithelial healing following the application of photorefractive keratectomy
Autologous serum eye-drops and enhanced epithelial healing time after photorefractive keratectomy
BackgroundThe aim of the study is to test whether use of autologous
serum eye-drops can provide earlier epithelial healing following the
application of photorefractive keratectomy.
MethodSixty patients (60 eyes) underwent photorefractive keratectomy for
myopia. Thirty eyes received autologous serum drops (Study group) while
30 eyes received conventional artificial tears (Control group) after
photorefractive keratectomy. An 8 mm epithelial opening was prepared
with the application of 18 per cent alcohol for 20 seconds.
Photorefractive keratectomy was performed using ESIRIS excimer laser
(SCHWIND, Kleinostheim, Germany) with an optic zone of 6.5 mm. Total
duration of epithelial healing was monitored as the main outcome
measure. The comparisons were done with chi-square test and independent
samples t-test. Statistical significance was considered at p < 0.05.
ResultsPreoperative myopic spherical refraction and ablation depths were
similar in the study and control groups. The mean duration for
epithelial healing was about one day shorter in the eyes receiving
autologous serum compared to the eyes receiving conventional treatment
(2.2 0.25 days versus 3 +/- 0 days, p = 0.001). All eyes achieved 6/7.5
or better uncorrected visual acuity in six months. In both groups, more
than 90 per cent of eyes were within +/- 0.50 D of emmetropia in 12
months. No significant difference was noted for the incidence of +1
haze.
ConclusionUse of autologous serum drops reduces epithelial healing
duration following surface ablation for two days
Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy
Background/ aim: To evaluate refractive and strabismic results and the
efficacy of intravitreal bevacizumab in retinopathy of prematurity (ROP)
ineligible for laser therapy.
Materials and methods: Thirty-nine eyes of 20 consecutive infants with
high-risk prethreshold ROP (11 infants with Zone I and 9 infants with
Zone II disease) who were ineligible for laser therapy due to systemic
and/ or ocular conditions were treated with intravitreal bevacizumab.
Recurrent retinopathy was treated with laser ablation. The final
follow-up examination was performed at 29.8 +/- 6.0 months of corrected
age.
Results: All eyes responded to the initial treatment with intravitreal
bevacizumab. ROP recurred in 8 eyes (36\%) with initial Zone I disease
and in only 2 eyes (11\%) with initial Zone II disease, which were
successfully treated with laser ablation. No eye developed myopia higher
than 5.0 diopters. At 2.5 years, the Zone I eyes that had received laser
treatment appeared to be more myopic than the Zone I eyes treated only
with intravitreal bevacizumab (P = 0.038). A tendency for a higher
incidence of strabismus after additional laser therapy was also noted,
but was not significant (P = 0.22).
Conclusion: Avoidance or even deferral of laser ablation with
intravitreal bevacizumab may lead to less myopization in ROP compared
with conventional laser treatment